AI’s Ability to Directly Impact Patient Outcomes | NCPDP 2025
Stanley V. Campbell, Jr., CEO of EagleForce Associates, Inc., and Yi Deng, PhD, Senior Vice President of Engineering at EagleForce, discuss how AI is being used to benefit patients.
Artificial intelligence has proved its ability to directly benefit patient outcomes. Whether it’s within clinical trials that lead to new discoveries or identifying new uses for a drug, AI has made its mark both within health care and in the pharmacy.
At the National Council for Prescription Drug Programs (NCPDP) 2025 Annual Conference, held May 5 to May 7 in Scottsdale, Arizona, Drug Topics was joined by Stanley V. Campbell, Jr., CEO, and Yi Deng, PhD, Senior Vice President of Engineering, of EagleForce Associates, Inc—a data analytics and advanced technology company helping pharmacies with a variety of necessary tasks.
Deng and Campbell sat down to explore the real-life examples of AI being used to improve patient benefits and save pharmacists time and money while doing so. They are helping pharmacies stay compliant with regulations and utilizing the most advanced tools to revolutionize how prescriptions are dispensed.
The duo explored how they are using AI in several different aspects to improve clinical trials, identify secondary uses for drugs, increase overall access to medications, and so much more. Watch this video to understand more about the complex and specific instances where AI can truly improve patients’ health.
Read more from our coverage of NCPDP 2025.
Ready to impress your pharmacy colleagues with the latest drug information, industry trends, and patient care tips? Sign up today for our free Drug Topics newsletter.
